The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation
文献类型：期刊论文
| 作者 | Jiang, Yuchen1,2; Peng, Xia1; Ji, Yinchun1; Dai, Yang1; Fang, Yanfen1; Xiong, Bing3 ; Ren, Wenming3; Hu, Youhong3; Chen, Yi1,2; Ai, Jing1,2
|
| 刊名 | MOLECULAR CANCER THERAPEUTICS
 |
| 出版日期 | 2021-11-01 |
| 卷号 | 20期号:11页码:2198-2206 |
| ISSN号 | 1535-7163 |
| DOI | 10.1158/1535-7163.MCT-21-0127 |
| 通讯作者 | Chen, Yi(ychen@simm.ac.cn) ; Ai, Jing(jai@simm.ac.cn) |
| 英文摘要 | Rearranged during transfection (RET), an oncogenic driver, has been found in multiple tumor types and is thus a promising anticancer therapeutic target. Novel selective RET inhibitors (RETi) that can overcome V804 gatekeeper mutations, endowing resistance to multikinase inhibitors (MKI) and, in particular, achieving KDR selectivity, are needed. In addition, the mechanisms underlying RET-inhibition-induced antiproliferative effects in the context of RET addiction are incompletely understood. This study describes a novel selective RETi, SYHA1815, which inhibited the kinase activity of RET wild type and V804 mutant with an IC50 in the subnanomolar to nanomolar range. Notably, SYHA1815 exhibited approximately 20-fold selectivity for RET over KDR, almost equivalent to that of the launched selective inhibitor pralsetinib. SYHA1815 had only a marginal inhibitory effect on cellular KDR signaling at a high (200 nmol/L) concentration, confirming the selectivity over KDR. In addition, SYHA1815 exhibited a favorable selectivity profile, with greater than 100-fold selectivity for RET over 347 other kinases. It exhibited potent antitumor efficacy and overcame V804 mutations in vitro and in vivo by targeting RET. Then, using SYHA1815 as a probe, we found that RET inhibition suppressed RET-driven cell proliferation via G(1) cell-cycle arrest through downregulating c-Myc. Furthermore, disruption of c-Myc upon Brd4 inhibitor treatment led to G(1) cell-cycle arrest and overrode RET-driven cell proliferation. Moreover, consistent with the marked in vivo efficacy of RET inhibition, the intratumoral c-Myc level was significantly decreased. In summary, SYHA1815 is a promising RETi for RET-aberrant cancer treatment that is currently in a phase I trial. |
| WOS关键词 | LUNG-CANCER ; OPEN-LABEL ; ACTIVATION ; RECEPTOR ; PHASE-2 ; GENE ; ALK |
| 资助项目 | Natural Science Foundation of China[81773762] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000715281700011 |
| 出版者 | AMER ASSOC CANCER RESEARCH |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/298701]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Chen, Yi; Ai, Jing |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai, Peoples R China 2.Univ Chinese Acad Sci, Beijing, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Jiang, Yuchen,Peng, Xia,Ji, Yinchun,et al. The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation[J]. MOLECULAR CANCER THERAPEUTICS,2021,20(11):2198-2206. |
| APA | Jiang, Yuchen.,Peng, Xia.,Ji, Yinchun.,Dai, Yang.,Fang, Yanfen.,...&Ai, Jing.(2021).The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation.MOLECULAR CANCER THERAPEUTICS,20(11),2198-2206. |
| MLA | Jiang, Yuchen,et al."The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation".MOLECULAR CANCER THERAPEUTICS 20.11(2021):2198-2206. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。